• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed

    2/25/21 2:55:38 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AIKI alert in real time by email
    SC 13D 1 sc_13d.htm SCHEDULE 13D Schedule 13D

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    AIKIDO PHARMA INC

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    008875106

    (CUSIP Number)

    FiveT Investment Management Ltd
    c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way
    Camana Bay, Grand Cayman, Cayman Islands KY1-1108
    +1 345 749 2552

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    February 17, 2021

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    1


    CUSIP No. 008875106

     

    13D

     

    Page 2 of 6 Pages

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    FiveT Investment Management Ltd

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    WC

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    00,000

     

    8.

     

    SHARED VOTING POWER
     
    00,000

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    00,000

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    00,000

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    00,000

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.00%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     

    2


    CUSIP No. 008875106

     

    13D

     

    Page 3 of 6 Pages

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    FiveT Capital AG

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    00,000

     

    8.

     

    SHARED VOTING POWER
     
    00,000

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    00,000

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    00,000

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    00,000

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.00%

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    IA

     

     

     

    3


    CUSIP No. 008875106

     

    13D

     

    Page 4 of 6 Pages

     

     

     

     

    Item 1.  Security and Issuer.

    Cusip:

    008875106

    Issuer:

    Aikido Pharma Inc
    One Rockefeller Plaza
    11th Floor
    New York, NY 10020

    Item 2.  Identity and Background.

    Name of person filing:

    FiveT Investment Management Ltd
    FiveT Capital AG

    Registered address or principle place of business:

    FiveT Investment Management Ltd
    c/o DMS Corporate Services, Suite 5B201, 2nd Floor, One Nexus Way,
    Camana Bay, Grand Cayman, Cayman Islands KY1-1108

    FiveT Capital AG
    Allmendstrasse 140, 8041 Zurich, ZH, Switzerland

     

    Item 5.  Interest in Securities of the Issuer.

    As of the date of this Schedule 13D, the Reporting Persons acquired an aggregate of 5,000,000 shares of Common Stock, consisting of 5,000,000 shares held by the FiveT Investment Management Ltd (the “Shares”).  The Shares represent 6.11% of the Common Stock outstanding.  Subsequently, the Reporting Persons sold an aggregate of 5,000,000 Shares.  As of the date of this Schedule 13D, the Reporting Persons beneficially own an aggregate of 0 shares of Common Stock. The Shares represent 0.00% of the Common Stock outstanding.

     

    Item 7.  Material to Be Filed as Exhibits.

    Schedule I

     

    4


    CUSIP No. 008875106

     

    13D

     

    Page 5 of 6 Pages

     

     

     

     

     

     

    Schedule I

     

    This Schedule sets forth information with respect to each purchase and sale of Shares which was effectuated by a Reporting Person in the last 60 days since the date of the event which requires filing of this Statement. 

    Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

     

    Trade Date

    Shares Purchased (Sold)

    Price Per Share ($)

    02/17/2021

    5,000,000

    1.60

    02/17/2021

    (5,000,000)

    1.65

     

     

     

     

    5


    CUSIP No. 008875106

     

    13D

     

    Page 6 of 6 Pages

     

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    FIVET INVESTMENT MANAGEMENT LTD

    /s/ Wieland Kreuder

    Authorized Person

    February 22, 2021

     

     

    6

    Get the next $AIKI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIKI

    DatePrice TargetRatingAnalyst
    10/11/2021$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AIKI
    SEC Filings

    View All

    AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    12/18/23 4:05:35 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    11/13/23 6:05:12 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 10-Q filed by AIkido Pharma Inc.

    10-Q - Dominari Holdings Inc. (0000012239) (Filer)

    11/6/23 4:47:02 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/28/23 8:00:33 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/28/23 8:00:36 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/22/23 6:00:41 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/28/23 8:00:33 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/28/23 8:00:36 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/26/23 6:43:23 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dominari Holdings Provides Update on Share Repurchase Program

    NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part

    12/28/22 9:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

    NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C

    12/22/22 8:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

    Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita

    11/28/22 9:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on AIkido Pharma with a new price target

    HC Wainwright & Co. initiated coverage of AIkido Pharma with a rating of Buy and set a new price target of $2.00

    10/11/21 6:14:44 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Financials

    Live finance-specific insights

    View All

    AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

    NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease.  The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system.  This patent application seeks patent protection for the use of ketamine and these peptides to treat Alzheimer's disease. We believe that one of the biggest breakthroughs in the study of depression has been the ob

    6/23/21 10:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Leadership Updates

    Live Leadership Updates

    View All

    AIkido Pharma Inc. Appoints New Director, Soo Yu

    New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company.  Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity.  The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule.  Further, Ms. Yu's background broadens t

    6/10/22 4:15:00 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

    NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public.  AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00.  As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad

    9/14/21 9:22:00 AM ET
    $AIKI
    $DATS
    Specialty Chemicals
    Consumer Discretionary
    Telecommunications Equipment
    Telecommunications

    AIkido Pharma Provides Business Update

    NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our

    4/5/21 9:00:00 AM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    $AIKI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by AIkido Pharma Inc.

    SC 13D - Dominari Holdings Inc. (0000012239) (Subject)

    12/28/23 4:15:22 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    12/28/23 4:05:18 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    7/6/23 4:30:08 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary